NCT02296112View on ClinicalTrials.gov

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

April 16, 2021

Conditions
Recurrent MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV Melanoma
Interventions
DRUG

trametinib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (4)

20007

Georgetown University Medical Center, Washington D.C.

37232

Vanderbilt-Ingram Cancer Center, Nashville

77030

M D Anderson Cancer Center, Houston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT02296112 - Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | Biotech Hunter | Biotech Hunter